Answers are grounded in this paper and cite their sources.
Background Intravenous nicotinamide adenine dinucleotide (IV NAD⁺) therapy has gained increasing popularity despite limited clinical evidence supporting its effectiveness. This study assessed knowledge, attitudes, and practices (KAP) regarding IV NAD⁺ therapy, perceived quality of life, and factors associated with selected treatment-related perceptions and intention to continue IV NAD⁺ therapy. Methods A cross-sectional study was conducted in 2025 among 100 adults receiving IV NAD⁺ therapy in physician-owned private clinics across Lebanon. The questionnaire included researcher-developed KAP items and selected quality-of-life items adapted from the SF-36 Health Survey. The questionnaire underwent forward–backward translation into Arabic. Descriptive statistics and Fisher's exact test were used for data analysis. Results The largest proportion of participants was aged 36–45 years (34%), and 65% were women. Moderate knowledge of IV NAD⁺ therapy was reported by 47% of participants. Sponsored social media (30%), healthcare professionals (29%), and family or friends (24%) were the primary sources of information, whereas only 4% reported scientific literature. Most participants perceived IV NAD⁺ therapy as moderately safe (49%), and 84% reported no adverse effects. Participants commonly reported favorable perceived health-related outcomes following IV NAD⁺ therapy, including better overall health than before therapy (75%), feeling full of energy at least a good bit of the time (73%), and improved mood (65%). Greater knowledge was significantly associated with belief in the age-related benefits of IV NAD⁺ therapy (p < 0.001) and intention to continue therapy (p = 0.019). Conclusion Adults residing in Lebanon receiving IV NAD⁺ therapy generally reported favorable perceptions regarding treatment safety and health-related well-being; however, information was frequently obtained from non-scientific sources. These findings reflect patient perceptions rather than objective clinical effectiveness. Prospective studies using validated outcome measures and objective clinical endpoints are warranted to establish the effectiveness and safety of IV NAD⁺ therapy.
No takes yet. Share an insight, caveat, or question.
Jebbawi et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: